insights_auto
Why is UCBJY up 2.55%?
Dive Deeperchevron_right
UCBJY:OTCMKTS
UCB Unsponsored Belgium ADR
$115.47
arrow_upward
+2.55%(+2.87) 1D
Oct 15, 4:00:00 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for UCBJY...
Open
$115.89
High
$116.39
Low
$115.15
Mkt. cap
39.35B
Avg. vol.
51.68K
Volume
74.77K
52-wk high
$168.76
52-wk low
$110.55
Beta
0.57
Shares outstanding
389.01M
No. of employees
9K
Open
$115.89
High
$116.39
Low
$115.15
Mkt. cap
39.35B
Avg. vol.
51.68K
Volume
74.77K
52-wk high
$168.76
52-wk low
$110.55
Beta
0.57
Shares outstanding
389.01M
No. of employees
9K
News stories
From web sources and news partners
ad-hoc-news.de
·
1 hour ago
UCB revises Bimzelx potential above EUR 7 billion: UCB stock sits 30.28 percent below its high
ad-hoc-news.de
·
1 day ago
UCB dedicates Georgia campus as UCB stock sits 29.15 percent below its high
Profile
UCB is a multinational biopharmaceutical company headquartered in Brussels, Belgium. UCB is an international company with revenue of €4.178 billion in 2016 which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson's disease, and Crohn's disease. The company's efforts are focused on treatments for severe diseases treated by specialists, particularly in the fields of central nervous system disorders, inflammatory disorders, and oncology.
Every three years, the company presents the UCB Award under the patronage of the Queen Elisabeth Medical Foundation to promote neuroscience research. The winner of this award is selected by an independent scientific committee. Wikipedia
About UCB Unsponsored Belgium ADR
CEOJean-Christophe Tellier
Employees9K
FoundedJan 18, 1928
Headquarters-
SectorPharmaceutical industry
Websiteucb.com